@Babydustt12
My initial report said "according to our internal data 89% of women with similar endometrial profile reached receptivity with one more day of progesterone administration, so in these cases new endometrial biopsy is not needed"
If they have said to repeat then I'd repeat as I don't think they say this very often.
My endometrium is a complicated story, it was initially 5mm before I did IVF, in IVF it got up to 8mm, one time even 9mm in medicated FETS, it's trilaminar but was always described as not quite right, it looks thin and patchy on transfer day. For the initial ERA it took my specialist 3 attempts, to get a biopsy, as it looked like the endometrium was there but only blood came out. I had a terrible microbiome which was treated and then the lining seemed to improve, it even got up to 8mm in a natural cycle. However I have recently found out I have hypothyroidism, this causes endometrial hyperplasia (a thicker lining). Now my thyroid hormones are in range my lining is back to being 5mm.
Endometrial receptivity is complicated, it's the progesterone that leads to receptivity. However it is likely that other things can cause issues with receptivity, the microbiome and immune issues for instance. This is why I repeated the ERA having treated the microbiome issue, unfortunately the repeat showed an ongoing issue with the microbiome. Since my endometrium has changed drastically since I treated my hypothyrodism I'm keen to repeat the ERA to see if I'm still a slow responder.
As for the ERA not being reliable, most of the studies on the ERA are from the lab that do the test. Some specialists think it's of no use at all.
CD138 is not to do with the ERA EMMA ALICE, it's a different test, it's a marker of endometritis, this is inflammation in the endometrium caused by bacteria. The ALICE test will tell you if you have the bacteria that cause it, since the market is negative that's a good thing. You could still have abnormal bacteria not associated with endometritis but that still aren't good bacteria to have.